Many employers and insurers are scaling back coverage and Medicare doesn’t cover the drugs for obesity. Meantime, some big ...
These findings support the claim that Medicare Advantage (MA) payments may be driven more by diagnosis and coding practices ...
Supplies of high-demand obesity drugs are improving – but they’re not easier to get - ‘There are a lot of people right now ...
This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.
Health plans are lobbying the Trump administration to scrap a proposal dating from the final days of the Biden administration that would require Medicare and Medicaid to cover anti-obesity drugs, ...